Efficacy and Safety of Oteseconazole in Recurrent Vulvovaginal Candidiasis.
Journal
NEJM evidence
ISSN: 2766-5526
Titre abrégé: NEJM Evid
Pays: United States
ID NLM: 9918317485806676
Informations de publication
Date de publication:
Aug 2022
Aug 2022
Historique:
medline:
1
8
2022
pubmed:
1
8
2022
entrez:
6
2
2024
Statut:
ppublish
Résumé
Oteseconazole for Recurrent Vulvovaginal CandidiasisThese two phase 3, multicenter RCTs evaluated the efficacy of oral oteseconazole in treating recurrent vulvovaginal candidiasis (RVVC). Among women with a history of RVVC, oteseconazole treatment through week 48 led to acute VVC recurrence in about 5% of patients compared to about 40% of patients receiving placebo, P<0.001. Oteseconazole showed potent activity against fluconazole-resistant
Identifiants
pubmed: 38319878
doi: 10.1056/EVIDoa2100055
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM